Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Stress exacerbates experimental Parkinson’s disease

Molecular Psychiatry volume 19, pages 638–640 (2014)Cite this article

Subjects

The influence of life stress on the progression of Parkinson’s disease (PD) has received little attention. Here, we examined the effects of chronic variable stress (CVS), a widely used animal model that recapitulates core symptoms of depression, on the course of neuronal degeneration and behavioral deficits in a rat neurotoxin model of PD. Depression is highly correlated with PD and is suggested to contribute more to the lowered quality of patient life than the debilitating motor symptoms.1 Despite the high prevalence of depression in PD patients, preclinical research on the comorbidity of these neuropsychiatric and neurodegenerative disorders remains at an early stage. Dysregulation of the stress response is purported to have a large role in the etiology/progression of depression, and many of the brain regions involved in stress regulation are also linked to depression.2, 3 Experimental stress or depression can lead to neurodegeneration, cellular atrophy or increased susceptibility to subsequent injury in numerous brain regions.4 Stress was long ago hypothesized to contribute to the neuropathology of PD, possibly by increasing the vulnerability of midbrain dopamine cells to degeneration.5 Given the strong connection between PD and depression, it is imperative to understand if chronic stress can be a complicating factor in disease progression or severity.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. McDonald WM, Richard IH, Delong MR . Biol Psychiatry 2003; 54: 363–375.

    Article  PubMed  Google Scholar 

  2. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM . Neuron 2002; 34: 13–25.

    Article  CAS  PubMed  Google Scholar 

  3. Herman JP, Ostrander MM, Mueller NK, Figueiredo H . Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1201–1213.

    Article  CAS  PubMed  Google Scholar 

  4. Duman RS . Eur Psychiatry 2002; 17 (Suppl 3): 306–310.

    Article  PubMed  Google Scholar 

  5. Smith AD, Castro CL, Zigmond MJ . Physiol Behav 2002; 77: 526–531.

    Article  Google Scholar 

  6. Smith LK, Jadavji NM, Colwell KL, Perehudoff KS, Metz GA . Eur J Neurosci 2008; 27: 2133–2146.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR . Mov Disord 2003; 18: 414–418.

    Article  PubMed  Google Scholar 

  8. Pålhagen SE, Carlsson M, Curman E, Wålinder J, Granérus AK . Acta Neurol Scand 2008; 117: 295–304.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grant NS060114 (KBS), Udall Parkinson’s Disease Centers of Excellence grant NS058830 (KBS, JPH), by grants from the Sunflower Revolution/University of Cincinnati Neuroscience Institute, Gardner Family Center for Parkinson’s Disease and Movement Disorders, Davis Phinney Foundation, Morris Braun Foundation, and Parkinson’s Disease Support Network of Ohio, Kentucky and Indiana (all KBS), a Scottish Rite Schizophrenia Foundation Fellowship (JWD), and a University Research Council Fellowship (AMH). We are grateful to Dr Sheila Fleming for valuable discussions and comments on the manuscript.

Author information

Author notes

  1. J W Dickerson

    Present address: 4Current address: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA,

Authors and Affiliations

  1. Department of Neurology, The Selma Schottenstein Harris Laboratory for Research in Parkinson’s, Gardner Family Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    A M Hemmerle, J W Dickerson & K B Seroogy

  2. Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, USA

    A M Hemmerle, J W Dickerson, J P Herman & K B Seroogy

  3. Department of Psychiatry and Behavioral Neuroscience, Stress Neurobiology Laboratory, Metabolic Diseases Institute, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    J P Herman

Authors
  1. A M Hemmerle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J W Dickerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J P Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K B Seroogy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to J P Herman or K B Seroogy.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hemmerle, A., Dickerson, J., Herman, J. et al. Stress exacerbates experimental Parkinson’s disease. Mol Psychiatry 19, 638–640 (2014). https://doi.org/10.1038/mp.2013.108

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2013.108

This article is cited by

Search

Advanced search

Quick links